---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-028622"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2025-04-03T23:59:59+00:00"
generated_at: "2026-05-23T22:31:28.081872+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology amends license agreement with Eisai, defers $8.2M in LYMPHIR payments to 2025

## Summary
- Total obligations owed to Eisai: $8,233,209.77 including $5.9M milestone and $2.33M development/inventory costs.
- Payment schedule: $2,535,317.77 by July 15, 2025; four monthly $2.35M payments; final $2,197,892.07 by Dec 15, 2025.
- Interest at 2% per annum on delayed amounts from original due dates.
- Parties released each other from claims related to late payment of milestone and other costs.

## SEC filing metadata
- accession: 0001213900-25-028622
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2025-04-03T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390025028622/0001213900-25-028622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390025028622/ea0237093-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-028622
- JSON: https://secwatch.observer/filing/0001213900-25-028622.json
- Plain text: https://secwatch.observer/filing/0001213900-25-028622.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.